title: Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia.
authors.affiliation: Department of Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Talley
mesh_terms: D000527:Alprostadil / Q000031:analogs & derivatives / Q000627:therapeutic use; D018118:Chloride Channels; D002986:Clinical Trials as Topic / Q000379:methods*; D003226:Congresses as Topic; D017277:Drug Approval; D004341:Drug Evaluation / Q000379:methods*; D004415:Dyspepsia / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D000068238:Lubiprostone; D014481:United States; D014486:United States Food and Drug Administration; D014922:Wisconsin
chemical_list: D018118:Chloride Channels; D005765:Gastrointestinal Agents; D000068238:Lubiprostone; D000527:Alprostadil